Galectin-3 expression in prostate cancer and benign prostate tissues: Correlation with biochemical recurrence

World Journal of Urology

Volumn 31, Issue 2, 2013, Pages 351-358

  Knapp, Judith S ^a   Lokeshwar, Soum D ^b   Vogel, Ulrich ^c   Hennenlotter, Jörg ^c   Schwentner, Christian ^c   Kramer, Mario W ^d   Stenzl, Arnulf ^c   Merseburger, Axel S ^d  

^a Diakonie Klinikum Stuttgart   (Germany)

^b UNIVERSITY OF MIAMI   (United States)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Biochemical recurrence; Galectin 3; Prostate cancer; Tissue microarray

Indexed keywords

EID: 84876435411     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-012-0925-y     Document Type: Article

References (32)

1. Jemal A, Siegel R, Xu J et al (2010) Cancer statistics. CA Cancer J Clin 60(5): 277-300.
2. Heidenreich A, Bellmunt J, Bolla M et al (2011) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59(1): 61-71.
3. Merseburger AS, Belka C, Behmenburg K et al (2008) Secondary hormonal manipulation. Front Radiat Ther Oncol 41: 93-102.
4. Moul JW, Merseburger AS, Srivastava S (2002) Molecular markers in prostate cancer: the role in preoperative staging. Clin Prostate Cancer 1(1): 42-50.
5. Kramer MW, Kuczyk MA, Hennenlotter J et al (2008) Decreased expression of galectin-3 predicts tumour recurrence in pTa bladder cancer. Oncol Rep 20(6): 1403-1408.
6. Merseburger AS, Kramer MW, Hennenlotter J et al (2008) Loss of galectin-3 expression correlates with clear cell renal carcinoma progression and reduced survival. World J Urol 26(6): 637-642.
7. Merseburger AS, Kramer MW, Hennenlotter J et al (2008) Involvement of decreased Galectin-3 expression in the pathogenesis and progression of prostate cancer. Prostate 68(1): 72-77.
8. Waalkes S, Merseburger AS, Simon A et al (2010) Galectin expression in urological cancer. Diagnostic, prognostic and therapeutic potential. Urologe A 49(3): 387-391.
9. Canesin G, Gonzalez-Peramato P, Palou J et al (2010) Galectin-3 expression is associated with bladder cancer progression and clinical outcome. Tumour Biol 31(4): 277-285.
10. Sakaki M, Fukumori T, Fukawa T et al (2010) Clinical significance of galectin-3 in clear cell renal cell carcinoma. J Med Invest 57(1-2): 152-157.
11. Ellerhorst J, Troncoso P, Xu XC et al (1999) Galectin-1 and galectin-3 expression in human prostate tissue and prostate cancer. Urol Res 27(5): 362-367.
12. Ellerhorst JA, Stephens LC, Nguyen T et al (2002) Effects of galectin-3 expression on growth and tumorigenicity of the prostate cancer cell line LNCaP. Prostate 50(1): 64-70.
13. Saraswati S, Block AS, Davidson MK et al (2011) Galectin-3 is a substrate for prostate specific antigen (PSA) in human seminal plasma. Prostate 71(2): 197-208.
14. Bartolazzi A, Gasbarri A, Papotti M et al (2001) Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet 357(9269): 1644-1650.
15. Meyer A, Coinac I, Bogdanova N et al. (2011) Apoptosis gene polymorphisms and risk of prostate cancer: a hospital-based study of German patients treated with brachytherapy. Urol Oncol (in Press).
16. Block AS, Saraswati S, Lichti CF et al (2011) Co-purification of Mac-2 binding protein with galectin-3 and association with prostasomes in human semen. Prostate 71(7): 711-721.
17. Merseburger AS, Kuczyk MA, Serth J et al (2003) Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissues. Oncol Rep 10(1): 223-228.
18. Vogel UF (2008) The construction of high-density paraffin tissue microarrays with 0. 43-mm-diameter paraffin tissue core biopsies is technically feasible. Virchows Arch 453(1): 43-46.
19. Merseburger AS, Hennenlotter J, Simon P et al (2005) Cathepsin D expression in renal cell cancer-clinical implications. Eur Urol 48(3): 519-526.
20. Deutscher SL, Figueroa SD, Kumar SR (2009) Tumor targeting and SPECT imaging properties of an (111)In-labeled galectin-3 binding peptide in prostate carcinoma. Nucl Med Biol 36(2): 137-146.
21. Than TH, Swethadri GK, Wong J et al (2008) Expression of Galectin-3 and Galectin-7 in thyroid malignancy as potential diagnostic indicators. Singapore Med J 49(4): 333-338.
22. Kim MK, Sung CO, Do IG et al (2011) Overexpression of Galectin-3 and its clinical significance in ovarian carcinoma. Int J Clin Oncol 16(4): 352-358.
23. Vereecken P, Awada A, Suciu S et al (2009) Evaluation of the prognostic significance of serum galectin-3 in American Joint Committee on Cancer stage III and stage IV melanoma patients. Melanoma Res 19(5): 316-320.
24. Johnson KD, Glinskii OV, Mossine VV et al (2007) Galectin-3 as a potential therapeutic target in tumors arising from malignant endothelia. Neoplasia 9(8): 662-670.
25. Kobayashi T, Shimura T, Yajima T et al (2011) Transient gene silencing of galectin-3 suppresses pancreatic cancer cell migration and invasion through degradation of β-catenin. Int J Cancer 129(12): 2775-2786.
26. Barondes SH, Cooper DN, Gitt MA et al (1994) Galectins. Structure and function of a large family of animal lectins. J Biol Chem 269(33): 20807-20810.
27. Konstantinov KN, Robbins BA, Liu FT (1996) Galectin-3, a beta-galactoside-binding animal lectin, is a marker of anaplastic large-cell lymphoma. Am J Pathol 148(1): 25-30.
28. Inohara H, Akahani S, Koths K et al (1996) Interactions between galectin-3 and Mac-2-binding protein mediate cell-cell adhesion. Cancer Res 56(19): 4530-4534.
29. Ahmed H, Banerjee PP, Vasta GR (2007) Differential expression of galectins in normal, benign and malignant prostate epithelial cells: silencing of galectin-3 expression in prostate cancer by its promoter methylation. Biochem Biophys Res Commun 358(1): 241-246.
30. van den Brule FA, Waltregny D, Liu FT et al (2000) Alteration of the cytoplasmic/nuclear expression pattern of galectin-3 correlates with prostate carcinoma progression. Int J Cancer 89(4): 361-367.
31. Pacis RA, Pilat MJ, Pienta KJ et al (2000) Decreased galectin-3 expression in prostate cancer. Prostate 44(2): 118-123.
32. Ahmed H, Cappello F, Rodolico V et al (2009) Evidence of heavy methylation in the galectin 3 promoter in early stages of prostate adenocarcinoma: development and validation of a methylated marker for early diagnosis of prostate cancer. Transl Oncol 2(3): 146-156.